The safety results with odanacatibThe number of patients with a drug-related adverse experience was similar between 50 mg odanacatib group and placebo . Likewise, the discontinuation rates were due to drug-related adverse experiences similar between the 50 mg odanacatib group and placebo . For the 50 mg odanacatib group, the most commonly drug-related adverse experiences, as examined by the investigators, nausea, headache, rash and muscle spasms. There was no dose-dependent increase in the incidence of side effects or skin infections of the upper respiratory tract was observed up to 24 months.
5) for 24 months. Participants were weekly with 5600 IU vitamin D and 500 mg of calcium carbonate was day to grant women with average daily calcium intake of less than 1000 mg from all sources. The primary endpoint was the LS mean change from baseline in BMD at the lumbar spine. To determinecondary endpoints included the LS mean change from baseline in BMD at the total hip, femoral neck, hip trochanter , and distal forearm, and based on changes in biochemical markers of bone turnover..The level of steroids hormone, in turn, causes essential changes in the animals the immune system, likely to influence the disease. Funding from the National Institutes of Allergy and Infectious Diseases supports this research.